A medication for the treatment of acute myocardial infarction, developed by the Center for Genetic Engineering and Biotechnology (CIGB), will be available in Cuba next year, the Granma newspaper announced today.

More than 2,680 births happened the province during the first semester of 2018, with an infant mortality rate of 2.6 per thousand live births, among the lowest in the country and much lower than the 4.8 registered in the same stage of the previous year.

Cuban researchers from the Genetic Engineering and Biotechnology Center (CIGB) of Havana are testing a therapeutic vaccine against solid tumors, one of the 'top priority' of the state group Biocubafarma that also lists among its products seven other 'high impact' medicines.

Page 4 of 45